What are the latest clinical trials for Endometrial Cancer in 2026

Latest Clinical Trials for Endometrial Cancer in 2026

I appreciate your question about current clinical trials. Based on the most recent NCCN Guidelines (Version 1.2026), I can share what the latest treatment approaches are, though I should note that specific trial enrollment information changes frequently and requires checking live trial databases.

Key Treatment Advances Reflected in 2026 Guidelines

According to the NCCN Guidelines for Endometrial Carcinoma (Version 1.2026), several important immunotherapy and combination approaches are now standard options:

1. Immunotherapy + Chemotherapy Combinations (First-Line)

For advanced or recurrent endometrial cancer, these combinations have shown strong results:

Dostarlimab + Chemotherapy (RUBY Trial)

• Dostarlimab (an immunotherapy drug) combined with carboplatin-paclitaxel chemotherapy
• FDA-approved for advanced/recurrent endometrial cancer
• The ENGOT-EN6/GOG-3031/RUBY trial showed improved overall survival

Pembrolizumab + Chemotherapy (KEYNOTE-B21)

• Pembrolizumab (another immunotherapy) plus chemotherapy with or without radiation
• ENGOT-en11/GOG-3053/KEYNOTE-B21 is a randomized phase III study for newly diagnosed high-risk endometrial cancer
• FDA-approved for primary advanced or recurrent endometrial carcinoma

Durvalumab + Chemotherapy (DUO-E Trial)

• Durvalumab combined with carboplatin/paclitaxel, with or without olaparib (a PARP inhibitor)
• Phase III trial for first-line treatment of advanced endometrial cancer
• FDA-approved for mismatch repair deficient cases

2. Targeted Therapies for Specific Biomarkers

For HER2-Positive Endometrial Cancer:

• Trastuzumab deruxtecan (an antibody-drug conjugate)
• DESTINY-PanTumor02 phase II trial showed efficacy in HER2-expressing solid tumors
• STATICE trial specifically studied this in uterine carcinosarcoma

For Mismatch Repair Deficient (MMR-d) Cancers:

• Dostarlimab monotherapy (for recurrent/advanced cases)
• Pembrolizumab (for microsatellite instability-high tumors)
• These immunotherapies work particularly well when the cancer has mismatch repair deficiency

3. Lenvatinib + Pembrolizumab (KEYNOTE-775)

• Combination of a targeted therapy (lenvatinib) with immunotherapy
• Study 309/KEYNOTE-775 showed improved outcomes in previously treated advanced endometrial cancer
• Now being studied as first-line treatment

How to Find Specific Trials You May Qualify For

To locate active clinical trials enrolling patients in 2026, I recommend:

1. ClinicalTrials.gov - Search "endometrial cancer" and filter by location and trial status
2. NCCN Member Institutions - Many major cancer centers have trials based on these guidelines
3. Your Oncologist - They can identify trials matching your specific cancer characteristics (stage, biomarkers, prior treatments)
4. Cancer Advocacy Organizations - Groups like the American Cancer Society can help connect you to trials

Important Questions to Ask Your Oncology Team

Since trial eligibility depends on your specific situation, ask your doctor:

1. "Based on my cancer's biomarkers (MMR status, HER2 status, tumor mutational burden), which trials would I be eligible for?"

2. "Are there immunotherapy combinations available as first-line treatment for my stage and type of endometrial cancer?"

3. "What are the differences in side effects between the dostarlimab, pembrolizumab, and durvalumab combinations?"

4. "If I've had prior treatment, what second-line trial options exist for my specific cancer characteristics?"

5. "How do I access the most current trial information, and how often is it updated?"

Why These Advances Matter

According to NCCN Guidelines, the shift toward immunotherapy combinations represents a significant change from traditional chemotherapy alone. These approaches work by:

• Activating your immune system to recognize cancer cells
• Combining immune activation with chemotherapy for stronger effects
• Targeting specific cancer mutations that make tumors more vulnerable

---

This information is for educational purposes only. Always consult your healthcare team for personalized medical advice and decisions about clinical trial eligibility.